ASCO Method For Valuing Cancer Drugs To Reflect Biopharma, Patient Input
ASCO hopes its method for assigning a value to cancer drugs will raise awareness among physicians and patients about how the cost of a treatment relates to its benefits.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.